Fig 1: An immune signature composite well separates two SSIS groups.a Unsupervised hierarchical clustering of the Spearman correlation matrix of 5 immune cell clusters, 6 gene sets, 10 genes, 7 cytokines and 2 clinical parameters for the four SARS-CoV-2pos groups. b Circos plot visualizing the Spearman correlation matrix of 5 immune cell clusters, 6 gene sets, 10 genes, 7 cytokines and 2 clinical parameters for the four SARS-CoV-2pos groups. Each line represents a significant correlation with P < 0.05. Lines indicate positive (red) or negative (red) correlations. Size of nodes indicates degree centrality, with larger nodes representing higher degree. c PCA of the 4 immune cell clusters (T04, M02, M03 and M04), 2 gene sets (innate immunity: macrophage infiltration; GO: osteoclast differentiation), 5 genes (FAM110B, PAK3, PPP1R17, UTS2 and CCR5), and 1 cytokine (STC1) for the asymptomatic and presymptomatic subjects. Each dot represents a subject, colored by disease status. d Concentration of plasma MMP-1 and STC1 measured by ELISA in the asymptomatic and presymptomatic subjects of the Cohort 1. e Heatmap depicting the expression of MMP-1 and STC1 measured by ELISA in the asymptomatic and presymptomatic subjects of the Cohort 1. f PCA of the expression of MMP-1 and STC1 measured by ELISA in the asymptomatic and presymptomatic subjects of the Cohort 1. Each dot represents a subject, colored by disease status. g Concentration of plasma MMP-1 and STC1 measured by ELISA in the asymptomatic and presymptomatic subjects of the Cohort 2. h Heatmap depicting the expression of MMP-1 and STC1 measured by ELISA in the asymptomatic and presymptomatic subjects of the Cohort 2. i PCA of the expression of MMP-1 and STC1 measured by ELISA in the asymptomatic and presymptomatic subjects of the Cohort 2. Each dot represents a subject, colored by disease status. Significance in d, g was determined by unpaired Wilcoxon test. *P < 0.05.
Fig 2: STC1 is a direct target gene of miR-606. (A) Venn diagram of the putative target genes of miR-606, determined using three miRNA target prediction programs. (B) Reverse transcription-quantitative PCR analysis of the relative expression levels of three putative target genes (ACVR1, DCLRE1A and STC1) in TNBC cells transfected with miR-606 mimics. (C) Western blot analysis of the protein expression levels of two putative target genes (DCLRE1A and STC1) in TNBC cells transfected with miR-606 mimics. (D) Secreted protein levels of STC1 in the supernatant of TNBC cells transfected with miR-606 mimics. (E) Protein expression levels of the target gene, STC1, in TNBC cells transfected with anti-miR-606. (F) Construction of the vector containing four putative miR-606 binding sites in the human STC1 3′-UTR. (G) Luciferase activity of TNBC cells co-transfected with the four indicated STC1 3′-UTR vectors and miR-606 mimics. Luciferase activity was measured 48 h post-co-transfection. Data are presented as the mean ± SEM. Data were analyzed using (B and D) Student's t-test and (G) one-way ANOVA. *P<0.05, **P<0.005 and ***P<0.001. TNBC, triple-negative breast cancer; ACVR1, activin A receptor, type 1; DCLRE1A, DNA cross-link repair 1A; STC1, Stanniocalcin 1; Cont, control; miR, microRNA.
Supplier Page from Abcam for Human Stanniocalcin 1 / STC ELISA Kit (STC1)